PeptideScanner
Find a supplier
Peptide Scanner does not sell peptides. Independent, not affiliated with any supplier. Disclaimer

Are peptides legal in the US?

Some peptides are legal in the US with a prescription. Since October 30, 2026, HHS says it will not act against a state-licensed pharmacy that compounds BPC-157, TB-500, Epitalon, MOTS-c, Semax or KPV for a named patient with a valid prescription. Selling them as “research use only” for people to use is still not a legal route.

6
peptides covered
174
prescription sellers ranked
11
sell with no prescription check
2
weeks for comments after publication (see the docket)

Updated October 30, 2026. Seller figures from our research on October 29, 2026. This is general information, not legal advice.

Information only. Not medical advice. A US-licensed prescriber decides. We do not sell, prescribe or take payment from these pharmacies.

What changed on October 30, 2026

HHS published a notice in the Federal Register, FR Doc 2026-22192. It announces a policy for six peptides. HHS says it will not take action against a state-licensed pharmacy, a federal facility or a licensed physician that compounds one of them, if all 10 conditions in the policy are met.

The notice is signed by Robert F. Kennedy, Jr., Secretary of Health and Human Services. Kennedy has backed wider access to peptides. NPR reports he has said he used some himself. At an FDA advisory panel in July, the panel voted for wider access to the six, but FDA's own scientists recommended against lifting the limits. Groups such as Public Citizen say the policy puts patients at risk.

HHS calls it a draft, interim policy. It lasts until FDA decides, by a final rule, whether each peptide goes on the 503A bulks list. It is not binding, and HHS says it may change it if a safety signal or a quality problem comes up.

Name
Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances
Federal Register
FR Doc 2026-22192, published October 30, 2026 (filed for public inspection October 28, 2026)
Docket
HHS-OASH-2026-0496 on regulations.gov
Type
Notice of availability of a draft enforcement policy. Not a law and not an FDA approval.
Signed by
Robert F. Kennedy, Jr., Secretary of Health and Human Services

How we got here

  • September 2023: FDA put the six peptides in Category 2, its list of ingredients with possible safety risks.
  • April 22, 2026: they left Category 2 because the people who nominated them withdrew the nominations. HHS says this did not change their legal status.
  • July 23 and 24, 2026: FDA's Pharmacy Compounding Advisory Committee voted in favor of the six. Its vote is advice only.
  • October 28, 2026: HHS filed the notice for public inspection. October 30, 2026: it was published in the Federal Register.
  • About November 13, 2026: the comment window closes, two weeks after publication. Check the docket for the exact closing date.

Covered by the HHS policy

  • One of the six peptides: BPC-157, TB-500, Epitalon, MOTS-c, Semax, KPV.
  • A valid prescription for you by name, from a prescriber licensed to prescribe under state law.
  • Made by a state-licensed pharmacy, a federal facility or a licensed physician (503A compounding).
  • One peptide per product. No blends.
  • Only in the forms HHS lists for each peptide (see the table below).
  • The ingredient comes from an FDA-registered maker, with a test certificate for each lot.
  • The label says “This is a compounded drug product. Not for resale.”
  • The pharmacy reports serious side effects and quality problems to FDA.

Not covered

  • Sales with no prescription, or labeled “research use only” or “not for human consumption”.
  • Blends, such as BPC-157 with TB-500, and peptides outside the six.
  • Forms HHS did not list, such as KPV by injection or Semax by injection.
  • 503B outsourcing facilities.
  • FDA approval. None of the six is approved, and compounded drugs are not FDA-approved.

State law still applies, and state pharmacy and medical boards can set their own rules.

Forms HHS lists for each peptide (Appendix B)
PeptideForm namedAllowed use
BPC-157BPC-157 acetateInjection under the skin or into muscle, oral, or topical.
TB-500TB-500 acetateInjection under the skin or into muscle only.
EpitalonEpitalon acetateInjection under the skin or into muscle, given in short courses, not continuously.
MOTS-cMOTS-c acetateInjection under the skin or into muscle only.
SemaxSemax free baseNasal use only.
KPVKPV acetateTopical or oral only. Not injection.

503A vs 503B, in plain words

Both are kinds of compounding, which means a pharmacist mixes a drug that is not a standard factory product. The names come from two sections of the federal drug law.

  • 503A: a state-licensed pharmacy, or a doctor, makes a drug for one named patient, based on a prescription. The HHS peptide policy covers 503A only.
  • 503B: an outsourcing facility registered with FDA makes larger batches. It must follow factory-style quality rules, and FDA inspects it. It can fill orders from hospitals or clinics with no named patient. The HHS peptide policy does not cover 503B.

The 503A bulks list and Category 1 and 2

A 503A pharmacy can only use a raw ingredient that meets one of three tests. It has an official quality standard, or it is part of a drug approved by the FDA, or it is on FDA's 503A bulks list. None of the six peptides passes these tests. That is why they needed a special policy.

While FDA builds the list, it sorts nominated ingredients into groups. Category 1 means FDA does not plan to act while it reviews the ingredient. Category 2 means FDA found possible safety risks, and it may act against a pharmacy that uses it. The six peptides were in Category 2 from 2023 until April 22, 2026.

Why “research use only” is not a route

Many websites sell peptides with a “research use only” or “not for human consumption” label. There is no prescriber, no named patient and no licensed pharmacy. The HHS policy does not cover these sales.

FDA looks past the label. In warning letters in 2026, FDA said that the seller's own website showed the products were meant for people. That made them unapproved new drugs, whatever the label said. The letters warn of seizure and court orders if the seller does not fix the problem.

HHS gave this as a reason for its policy. It said research-use-only peptides from foreign makers pose a safety risk to US patients. It wants to give patients a more controlled option.

We found 11 US-facing sellers of covered peptides with no prescription check. 6 of them have an FDA warning letter. See the list and the evidence.

How to check a provider

  • A prescriber reviews you before you pay. A site that takes your card first is a warning sign.
  • The prescriber is licensed in the state where you are. In most states, a telehealth visit counts as care given where the patient is.
  • The pharmacy is named, and its license is active on the state board.
  • One peptide per product, in a form HHS lists.
  • No “research use only” wording anywhere on the site.
  • A test certificate for each lot, and the policy label on the product.

We checked 250 US sellers against these points. 174 are ranked, 65 were checked but not ranked, and 11 sell with no prescription check. See the ranked list or read how we score sellers.

The public comment window

The Federal Register notice says written comments are accepted “until 2 weeks after date of publication in the Federal Register”. It was published on October 30, 2026. So comments are accepted until about November 13, 2026 (two weeks after publication); check the docket for the exact closing date. Comments go through regulations.gov, on docket HHS-OASH-2026-0496.

The notice does not give a calendar date, and the date above is our own count. HHS may change the policy after it reads the comments.

Read FR Doc 2026-22192 · Open docket HHS-OASH-2026-0496

Questions

Are peptides legal in the US?

Some are, with a prescription. Peptide drugs approved by the FDA, such as insulin, are legal with a prescription. Since October 30, 2026, HHS says it will not act against a state-licensed pharmacy that compounds BPC-157, TB-500, Epitalon, MOTS-c, Semax and KPV for a named patient with a valid prescription. Selling them for people to use without a prescription, including as "research use only", is not covered.

What did RFK Jr. do about peptides?

As HHS Secretary, Robert F. Kennedy Jr. signed FR Doc 2026-22192. It says HHS will not take action against licensed pharmacies and doctors that compound the six peptides under 10 conditions. It is not an FDA approval, and HHS says it can change the policy if a safety or quality problem comes up.

Is BPC-157 legal now?

HHS says it will not act against a state-licensed 503A pharmacy that compounds BPC-157 for a named patient with a valid prescription. It must be BPC-157 alone, not a blend, in the forms the policy lists. It is still not FDA-approved, and it is still not on FDA's 503A bulks list.

Is it legal to buy research-use-only peptides?

The HHS policy does not cover them. FDA has sent warning letters to online sellers saying a "research use only" label does not stop a product from being an unapproved drug when the seller's own site points to human use. Those letters go to sellers. HHS says research-use-only peptides from foreign makers pose a safety risk to US patients. We found 11 US-facing sellers of covered peptides with no prescription check.

What is the difference between 503A and 503B?

A 503A pharmacy compounds a drug for one named patient, based on a prescription. A 503B outsourcing facility makes larger batches, registers with FDA and follows factory-style quality rules. The HHS peptide policy covers 503A compounding only. 503B outsourcing facilities are not covered.

Do I need a prescriber in my own state?

In most states, yes. State medical boards treat a telehealth visit as care given where the patient is. So the prescriber needs a license, or another approval, in the state where you are. Check your state medical board if you are unsure.

Can I comment on the policy?

Yes. The Federal Register notice takes written comments on regulations.gov, docket HHS-OASH-2026-0496, until 2 weeks after it was published on October 30, 2026. That is about November 13, 2026 (two weeks after publication); check the docket for the exact closing date.

Does the policy mean these peptides are safe?

No. HHS says compounded drugs are not FDA-approved, so FDA does not review their safety, effectiveness or quality before they are sold. Human evidence for most of the six is thin. A licensed prescriber should weigh the risks with you.

Sources

Each source was checked on the date shown. We do not link to seller websites.

This is general information, not legal advice. Rules can change. For your own case, talk to a licensed prescriber or a lawyer in your state.